convenience sample of patients having their BMX at our center was utilized. We reviewed patients BMX results a week following the BMX procedure to monitor job performance of the BMX staff. Data collected included diagnosis, gross bone marrow core length, evaluable bone marrow core, and pathology reported bone marrow aspirate hemodilution. For this review PCD included MM, Monoclonal gammopathy of undetermined significance (MGUS), and Amyloidosis. MPD included Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), and Myelofibrosis (MF). Results: Our data showed that the mean bone marrow core length among all samples was 1.9 centimeters (cm) with the average evaluable bone marrow core length being 1.3 cm. Mean PCD bone marrow core length was found to be much lower at 1.6 cm with evaluable core length of 1.1 cm. Our mean hemodiluted bone marrow aspirates rate was 12.2%. The percent of CLL hemodiluted bone marrow aspirate was 15.4% which included 2 dry taps and MPD was 17.3% and included 1 dry tap. Of interest, the percent of hemodiluted samples seen in patients with Mastocytosis was 55.6%. In reviewing our data, we noted that only 19 of 3199 patients had a dry tap which seems quite low. It is our thought that this is a reflection of the patient population we treat. Most of the newly diagnosed AML's have their BMX in the hospital. See chart for full data compilation. Conclusion: In our review, it appears that plasma dyscrasias have a bone marrow core less than the average reviewed and CLL, MPD, and Mastocytosis have a higher hemodilution rate in comparison. We are going to review the data further to see if differences can be seen in older vs. younger patients. Of the 604 patients, 402 (67%) received consolidation and 202 (33%) received none. Those who received consolidation therapy had a higher percentage of exposure to 7+3 or similar induction regimens (89% versus 78%, P < .01), a higher percentage of CR1 after 1 cycle of induction (81% versus 67% %, P < .01), a higher percentage of intermediate risk karyotype (48% versus 38%, P ¼ .03), and a higher proportion of ATG or Campath exposure (42% versus 34%, P ¼ .06). Those receiving no consolidation more frequently received Fludarabine + Melphalan conditioning (25% versus 13%, P ¼ .01) and had a pre-existing MDS/MPD (34% versus 19%, P < .01). Donor source and GVHD prophylaxis were similar between groups. Results: Univariate analysis revealed similar rates of engraftment, acute and chronic graft versus host disease (GVHD), relapse incidence, TRM, OS and DFS between groups (Table 1) . Multivariate analysis confirmed the lack of impact of pre-HCT consolidation on relapse, TRM, OS, or DFS. Higher (> 2 grams/m2/day) versus lower dose cytarabine did not influence results. Unfavorable karyotype was the main factor associated with higher rates of relapse (HR 1.865, P < .0001) and was also associated with inferior OS (HR 1.74, P < .001) and DFS (HR 1.645, P < .0001). Conclusion: Post transplant outcomes are not improved by pre-HCT consolidation therapy prior to RIC conditioning. Based on these data, donor searches for eligible patients should begin soon after AML diagnosis to facilitate transition to HCT upon CR1 without delay. 
